Want to join the conversation?
$BCR 2Q15 Call: PMA supplement for 120/150 mm balloon lengths was recently approved & received IDE approval, enrolled first few patients in AV access drug-coated balloon study. We're also working toward launch in 1H16 of next generation of both PowerGlide &AccuCath products. For acute hemodialysis patients, recently launched Trialysis Slim catheter
$YHOO is reporting today after market close. Nobody cares about this stock.
$WBA is yet to receive US anti-trust clearance for its Rite Aid acquisition. The deadline for the deal expires on January 27.
$BMY plunge 7.2%. No credits to the non-acceleration of approval for lung cancer combination treatment.